Posted by Michael Wonder on 12 Jul 2021
Leukaemia patients demand reimbursement for Novartis’ Kymriah
12 July 2021 - Korean leukaemia patients have urged the government to provide rapid reimbursement of Kymriah, the first CAR-T (chimeric antigen receptor-T) treatment for end-stage leukaemia-lymphoma developed by Novartis.
In a statement issued last Friday, the Korea Leukaemia Patients Organisation reiterated its request to the government to expedite the reimbursement of Kymriah at its fifth Cancer Disease Review Committee meeting scheduled for Wednesday.
